Anlotinib improves overall survival in relapsed SCLC
Results of ALTER 1202 reveal survival benefit for anlotinib third-line in small-cell lung cancer
Cediranib–olaparib combination is effective regardless of disease mutations
Results from the BAROCCO trial may help define the optimum treatment schedule for an antiangiogenic–PARP inhibitor combination in recurrent, platinum-resistant ovarian cancer
From research bench to the patient’s bedside
ESMO Congress 2019 held in Barcelona, Spain, from 27 September to 1 October 2019
Adding FOLFIRINOX to nab-PG may improve outcomes in pancreatic cancer
Results from the phase II NEOLAP study presented at ESMO 2019
Oncologists can have a pivotal role in health policy
Effective NCCPs should help medical oncologists to provide better cancer care, but they cannot work in isolation